Silverarc Capital Management’s BlossomHill Therapeutics BLSM Stock Holding History

Silverarc Capital Management’s Portfolio BLSM Stock Details BLSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.77M	Buy	+202,104	New	+$4.02M	0.44%	46

Other funds holding BLSM

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Monashee Investment Management Boston, Massachusetts $33.4M AUM 92.4% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Aster Capital Management Dubai, United Arab Emirates $275M AUM 18.46% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

Silverarc Capital Management's BLSM Position: Q3 2026 in Review

Silverarc Capital Management opened a new position in BlossomHill Therapeutics (BLSM) in Q3 2026: 202,104 shares worth $3.77M. The stake represents 0.44% of the portfolio and ranks #46 among its holdings.

11 funds tracked by Wall St. Rank hold BLSM as of Q3 2026.

Silverarc Capital Management held 202,104 shares of BlossomHill Therapeutics worth $3.77M as of Q3 2026.
BlossomHill Therapeutics was a new Silverarc Capital Management position in Q3 2026.
BlossomHill Therapeutics made up 0.44% of Silverarc Capital Management's portfolio in Q3 2026, its #46 holding.
11 funds tracked by Wall St. Rank held BlossomHill Therapeutics as of Q3 2026.

Based on Silverarc Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.